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Familial hypertrophic cardiomyopathy (HCM) is a pre-
valent hereditary cardiacdisorder linked toarrhythmia
and sudden cardiac death. While the causes of HCM
have been identified as genetic mutations in the
cardiac sarcomere, the pathways by which sarco-
meric mutations engender myocyte hypertrophy and
electrophysiological abnormalities are not under-
stood. To elucidate the mechanisms underlying
HCM development, we generated patient-specific
induced pluripotent stem cell cardiomyocytes (iPSC-
CMs) from a ten-member family cohort carrying
a hereditary HCM missense mutation (Arg663His) in
the MYH7 gene. Diseased iPSC-CMs recapitulated
numerous aspects of the HCM phenotype including
cellular enlargement and contractile arrhythmia at
the single-cell level. Calcium (Ca2+) imaging indicated
dysregulation ofCa2+ cycling andelevation in intracel-
lular Ca2+ ([Ca2+]i) are central mechanisms for disease
pathogenesis. Pharmacological restoration of Ca2+
homeostasis prevented development of hypertrophy
and electrophysiological irregularities. We anticipate
that these findingswill help elucidate themechanisms
underlying HCM development and identify novel
therapies for the disease.
INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is an autosomal dominant
disease of the cardiac sarcomere and is estimated to be theCemost prevalent hereditary heart condition in the world (Maron
et al., 1995; Teare, 1958). Patients with HCM exhibit abnormal
thickening of the left ventricular (LV) myocardium in the absence
of increased hemodynamic burden and are at heightened risk
for clinical complications such as progressive heart failure,
arrhythmia, and sudden cardiac death (SCD) (Maron, 2002;
Maron et al., 2003). Molecular genetic studies from the past
two decades have demonstrated that HCM is caused by muta-
tions in genes encoding for proteins in the cardiac sarcomere
(Geisterfer-Lowrance et al., 1990; Seidman and Seidman,
2001). While identification of specific mutations has defined
the genetic causes of HCM, the pathways by which sarcomeric
mutations lead to myocyte hypertrophy and ventricular
arrhythmia are not well understood. Efforts to elucidate the
mechanisms underlying development of HCM have yielded con-
flicting results, paradoxically supporting models of both loss in
myosin function and gain in myosin function to explain develop-
ment of the disease (Arad et al., 2002; Marian et al., 1997; Tyska
et al., 2000).
Attempts to resolve these discrepancies have been hampered
by difficulties in obtaining human cardiac tissue and the inability
to propagate heart samples in culture. To circumvent these
hurdles, we generated induced pluripotent stem cell-derived
cardiomyocytes (iPSC-CMs) from a family of ten individuals,
half of whom carry an autosomal dominant missense mutation
on exon 18 of the b-myosin heavy chain gene (MYH7) encoding
for an Arginine to Histidine substitution at amino acid position
663 (Arg663His). We report here that the generation of patient-
specific iPSC-CMs allows for recapitulation of the HCM disease
phenotype at the single-cell level and that elevation in intracel-
lular Ca2+ ([Ca2+]i) is a central mechanism underlying pathogen-
esis of the disease. These findings validate iPSC technology as
a method to understand how sarcomeric mutations cause thell Stem Cell 12, 101–113, January 3, 2013 ª2013 Elsevier Inc. 101
Figure 1. Derivation and Characterization of Patient-Specific iPSCs
(A) Representative long-axis MRI images of the proband and a control matched family member at end systole and end diastole demonstrating asymmetric
hypertrophy of the inferior wall. See also Figure S1A and Movie S1.
(B) Confirmation of the Arg663Hismissensemutation on exon 18 of theMYH7 gene in HCMpatients (II-1, III-1, III-2, III-3, and III-8) by PCR and sequence analysis.
(C) Schematic pedigree of the proband carrying the Arg663His mutation in MYH7 recruited for this study (II-1) as well as her husband (II-2) and eight children (III-1
through III-8). Circles represent female family members and squares represent males. Solid symbols indicate clinical presentation of the HCM phenotype,
whereas open symbols represent absence of presentation. ‘‘+’’ and ‘‘’’ signs underneath family members indicate presence and absence of the Arg663His
mutation, respectively. Two individuals (III-3 and III-8) were found to carry the Arg663His mutation but had yet to present the HCM phenotype due to young age.
See also Table S1.
(legend continued on next page)
Cell Stem Cell
Modeling HCM Using Patient-Specific iPSC-CMs
102 Cell Stem Cell 12, 101–113, January 3, 2013 ª2013 Elsevier Inc.
Cell Stem Cell
Modeling HCM Using Patient-Specific iPSC-CMsdevelopment of HCM and to identify new therapeutic targets for
the disease.
RESULTS
Recruitment of HCM Family Cohort and Evaluation
of Disease Genotype and Phenotype
A ten-member family cohort that spanned two generations (II
and III) was recruited for isolation of dermal fibroblasts. The
proband was a 53-year-old African American female patient
(II-1) who presented at the hospital with palpitations, shortness
of breath, and exertional chest pain. Results from comprehen-
sive testing revealed concentric left ventricular hypertrophy
(LVH) with prominent thickening of the inferior septum and infe-
rior wall (Figure 1A and see Figure S1A, Table S1, and Movie S1
available online). To confirm presence of an HCM-causing muta-
tion, we screened the proband’s genomic DNA for mutations
with a panel of 18 genes associated with HCM including
ACTC1, CAV3, GLA, LAMP2, MTTG, MTTI, MTTK, MTTQ,
MYBPC3, MYH7, MYL2, MYL3, PRKAG2, TNNC1, TNNI3,
TNNT2, TPMI, and TTR. Nucleotide sequence analysis demon-
strated a known familial HCM missense mutation on exon 18
of the b-myosin heavy chain (MYH7) gene, which causes an
Arginine to Histidine substitution at amino acid position 663
(Arg663His; Figure 1B) (Gruver et al., 1999). Subsequent genetic
evaluation of the proband’s family revealed that four of her eight
children (III-1, III-2, III-3, and III-8; ages 21, 18, 14, and 10) carried
the Arg663His mutation (Figure 1C). The proband’s family under-
went the same comprehensive clinical evaluation, which re-
vealed mild LVH in the two eldest carriers on echocardiography
and MRI as well as occasional premature ventricular contrac-
tions on ambulatory monitoring. The two younger carriers (III-3
and III-8; ages 14 and 10) had not fully developed the phenotype
due to their young age but did exhibit hyperdynamic function by
echocardiography (summarized in Table S1). As onset of HCM
typically occurs after 18 years of age, these clinical findings
were typical for preadolescent and adolescent mutant carriers
who later manifest the disease in adulthood. The proband’s
husband (II-2; age 55) and other four children (III-4, III-5, III-6,
and III-7; ages 20, 16, 14, and 13) did not carry the mutation or
exhibit any cardiac abnormalities upon examination.
Generation of Patient-Specific iPSCs and Confirmation
of Pluripotency
Patient-specific iPSCs were generated from primary fibroblasts
of all ten individuals through lentiviral infection with the reprog-
ramming factors Oct-4, Sox-2, Klf-4, and c-Myc. A minimum of
three distinct lines was generated per patient and assayed for(D) Brightfield and immunofluorescencemicroscopy photographs of patient-spec
fibroblasts, alkaline phosphatase (AP) staining of pluripotent colonies, and marke
NANOG. See also Figures S1B–S1G.
(E) Quantitative bisulfite pyrosequencing of the methylation status of Nanog and O
members with HCM (II-1, III-1, III-2, III-3, and III-8) and five control matched family
used as negative and positive controls, respectively.
(F) Ratios of quantitative PCR values for total versus endogenous expression o
iPSC lines derived from five HCM (II-1, III-1, III-2, III-3, and III-8) and five control (II
used as controls.
(G) Scatter plots comparing whole genome expression of patient-specific iPSC lin
samples (n = 13,044) were selected for Pearson correlation analysis. Error bars r
Cepluripotency through a battery of tests. Established iPSCs ex-
hibited positive immunostaining for the ESC markers SSEA-4,
TRA-1-60, TRA-1-81, OCT4, SOX2, NANOG, and alkaline phos-
phatase, as well as protein expression for the transcription
factors OCT4, SOX2, and NANOG (Figure 1D, Figure S1B).
Quantitative bisulfite pyrosequencing and quantitative RT-PCR
demonstrated hypomethylation of NANOG and OCT4 pro-
moters, activation of endogenous pluripotency transcription
factors, and silencing of lentiviral transgenes (Figures 1E and
1F). Microarray analyses comparing whole-genome expression
profiles of dermal fibroblasts, iPSCs, and human ESCs (WA09
line) further confirmed successful reprogramming of all cell lines
(Figure 1G). Karyotyping demonstrated stable chromosomal
integrity in all iPSC lines through passage 30 (Figure S1C). Spon-
taneous embryoid body (EB) and teratoma formation assays
yielded cellular derivatives of all three germ layers in vitro and
in vivo, confirming the pluripotent nature of generated iPSCs
(Figures S1D–S1F). Restriction enzyme digestion and se-
quencing verified the presence and absence of the Arg663His
mutation in the MYH7 locus of HCM and control iPSCs, respec-
tively (Figure S1G).
Differentiation of Patient-Specific iPSCs into
Cardiomyocytes
Established iPSC lines from all subjects were differentiated into
cardiomyocyte lineages (iPSC-CMs) using standard three-
dimensional (3D) EB differentiation protocols (Yang et al.,
2008). Ten to twenty days after the initiation of differentiation,
spontaneously contracting EBs were observed to appear under
light microscopy. Immunostaining for cardiac Troponin T indi-
cated that beating EBs from both control and HCM iPSC lines
contained cardiomyocyte purities between 60%–80% (Figures
S2A and S2B). Beating EBs were seeded onmultielectrode array
(MEA) probes for evaluation of electrophysiological properties.
Both control and HCM iPSC-derived EBs exhibited comparable
beat frequencies, field potentials, and upstroke velocities at
baseline (Table S2). EBs were subsequently dissociated into
single iPSC-CMs and plated on gelatin-coated chamber slides
for further analysis. Single dissociated iPSC-CMs from both
HCM and control family members maintained spontaneous
contraction and exhibited positive staining for sarcomeric
proteins such as cardiac troponin T and myosin light chain
(MLC)2a and MLC2v (Figure 2A and Figures S2C and S2D).
iPSC-CMs Carrying the Arg663His Mutation
Recapitulate HCM Phenotype In Vitro
After cardiac differentiation and dissociation to single beat-
ing cells, diseased and control-matched iPSC-CMs wereific dermal fibroblasts, representative iPSC colony derived frompatient-specific
rs of pluripotency including TRA-1-60, OCT4, TRA-1-81, SOX2, SSEA-4, and
ct4 promoter regions in ten patient-specific iPSC lines derived from five family
members (II-2, III-4, III-5, III-6, and III-7). Fibroblasts and H7 human ESCs were
f the Yamanaka factors OCT4, SOX2, c-MYC, and KLF4 in patient-specific
-2, III-4, III-5, III-6, and III-7) family members. Human ESC from the H7 line was
es, H7 ESCs, and dermal fibroblasts. Genes with SD greater than 0.2 among all
epresent SEM.
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Figure 2. Generation and Characterization of Patient-Specific HCM iPSC-CMs
(A) Representative immunostaining for cardiac troponin T and F-actin demonstrating increased cellular size and multinucleation in HCM iPSC-CMs as compared
to control iPSC-CMs. See also Figures S2A–S2D.
(B) Quantification of cell size for five control iPSC-CM lines (II-2, III-4, III-5, III-6, and III-7) (n = 55 per patient line) and five HCM iPSC-CM lines (II-1, III-1, III-2, III-3,
and III-8) (n = 59 per patient line) 40 days after induction of cardiac differentiation.
(C) Quantification of multinucleation in control (n = 55, 5 control subject lines) and HCM (n = 59, 5 patient lines) iPSC-CMs.
(D) Representative immunofluorescence staining reveals elevated ANF expression in theMLC2v-positive ventricular HCM iPSC-CMs as compared to controls.
(E) Changes in ANF gene expression as measured by single-cell quantitative PCR in control and HCM iPSC-CMs at days 20, 30, and 40 after induction of cardiac
differentiation (n = 32 per time point, 5 control subject and 5 patient lines).
(F) Quantification of MYH7/MYH6 expression ratio in HCM iPSC-CMs and controls (n = 32 per time point, 5 control subject and 5 patient lines).
(G) Representative immunofluorescence staining images revealing nuclear translocation of NFATC4 in HCM iPSC-CMs.
(H) Percentage of cardiomyocytes exhibiting positive NFATC4 staining in control (n = 187, 5 control subject lines) and HCM (n = 169, 5 patient lines) iPSC-CMs.
(I) Quantification of cell size in control and HCM iPSC-CMs after treatment with calcineurin inhibitors CsA and FK506 for 5 continuous days (n = 50, 5 control
subject and 5 patient lines per group). See also Figures S2E–S2I.
(J) Heat map representations of gene expression in single control and HCM iPSC-CMs for genes associated with cardiac hypertrophy at days 20, 30, and 40 after
induction of cardiac differentiation. See also Figure S3A. *p < 0.05 HCM versus control, **p < 0.0001 HCM versus control. Error bars represent SEM.
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Hypertrophic iPSC-CMs exhibited features of HCM such as
cellular enlargement and multinucleation beginning in the sixth
week after induction of cardiac differentiation (Arad et al.,
2002). At day 40 postinduction, HCM iPSC-CMswere noticeably
larger (1847 ± 507 pixels; n = 295, 5 patient lines) than control
matched iPSC-CMs (1146 ± 355 pixels; n = 265, 5 control104 Cell Stem Cell 12, 101–113, January 3, 2013 ª2013 Elsevier Inc.subject lines) and exhibited significantly higher frequencies of
multinucleation (HCM: 48.3% ± 8.7%; n = 288, 5 patient lines
versus control: 22.1% ± 3.4%; n = 275, 5 control subject lines)
(Figures 2A–2C). Mutant iPSC-CMs also demonstrated other
hallmarks of HCM including expression of atrial natriuretic factor
(ANF), elevation of b-myosin/a-myosin ratio, calcineurin activa-
tion, and nuclear translocation of nuclear factor of activated
Cell Stem Cell
Modeling HCM Using Patient-Specific iPSC-CMsT cells (NFAT) as detected by immunostaining (Figures 2D–2H,
Figures S2E and S2F) (Seidman and Seidman, 2001). Analysis
of myofibrils by immunofluorescence microscopy revealed
further characteristics of HCM in mutant iPSC-CMs such as
increased myofibril content (HCM TNNT2 fluorescence inten-
sity = 7.39 ± 0.53 3 105, n = 186, 5 patient lines; control
TNNT2 fluorescence intensity = 3.60 ± 0.26 3 105, n = 173, 5
control subject lines) and a higher percentage of cells exhibiting
disorganized sarcomeres (HCM = 16.5% ± 3.6%, n = 186, 5
patient lines; control = 6.6% ± 1.7%, n = 173, 5 control subject
lines) (Figures S2G–S2I).
As calcineurin-NFAT signaling is a key transcriptional activator
for induction of hypertrophy in adult cardiomyocytes, we sought
to test the importance of this pathway to hypertrophic develop-
ment in HCM iPSC-CMs (Molkentin et al., 1998). Blockade of cal-
cineurin-NFAT interaction in HCM iPSC-CMs by cyclosporin A
(CsA) and FK506 reduced hypertrophy by over 40% (Figure 2I).
Specificity of CsA and FK506 to disrupt nuclear translocation
of NFAT was confirmed by immunostaining (Figures S2E
and S2F). In the absence of inhibition, NFAT-activatedmediators
of hypertrophy such as GATA4 and MEF2C were found to be
significantly upregulated in HCM iPSC-CMs beginning day 40
postinduction of cardiac differentiation but not prior to this point
(Figure S3A). Taken together, these results indicate that calci-
neurin-NFAT signaling plays a central role in the development
of the HCM phenotype as caused by the Arg663His mutation.
Single-Cell Gene Expression Profiling Demonstrates
Activation of HCM-Associated Genes
Clinical presentation of HCM typically occurs over the course of
several decades in affected individuals (Maron, 2002). To inves-
tigate the temporal effects of the Arg663His mutation upon HCM
development at the cellular level, we assessed the expression of
hypertrophic-related genes in single purified iPSC-CMs from
both HCM and control patients. Single contracting cardiomyo-
cytes were manually lifted from culture dishes at days 20, 30,
and 40 from initiation of differentiation and subjected to single-
cell quantitative PCR analysis using a panel of cardiomyocyte-
related transcripts (Narsinh et al., 2011b). Beginning at day 40,
hypertrophic-related genes such as GATA4, TNNT2, MYL2,
andMYH7were found to be upregulated in HCM iPSC-CMs (Fig-
ure 2J, Figure S3A). No significant increases in expression of
HCM-related genes were found prior to this time point.
iPSC-CMs Carrying the Arg663His Mutation Exhibit
Electrophysiological and Contractile Arrhythmia
at the Single-Cell Level
Arrhythmia is a clinical hallmark of HCM and is responsible for
a significant portion of morbidity and mortality associated with
the disease including sudden cardiac death (Maron, 2002;
Maron et al., 1996).We therefore next examined the electrophys-
iological properties of iPSC-CMs carrying the Arg663His muta-
tion by whole-cell patch clamping. Both HCM and control
iPSC-CMs contained myocyte populations characterized by
nodal-like, ventricular-like, and atrial-like electrical waveforms,
resting membrane potentials, and velocity upstrokes (Figures
S3B–S3G). Capacitance measurements of ventricular-type
iPSC-CMs indicated HCM cells (62.5 ± 5.8 pF, n = 20, 5 patient
lines) were larger than control counterparts (36.1 ± 3.2 pF, n = 19,Ce5 control subject lines) (Figure S3H). In the first 4 weeks after
induction of differentiation, cells from both groups displayed
similar action potential frequencies, peak amplitudes, and
resting potentials. However, starting at day 30, a large subfrac-
tion (40.4% ± 12.9%; n = 131, 5 patient lines) of HCM myocytes
as compared to controls (5.1%±7.1%; n = 144, 5 control subject
lines) were observed to exhibit arrhythmic waveforms including
frequent small depolarizations that resembled delayed afterde-
polarizations (DADs) that failed to trigger action potentials and
clustered beats (Figures 3A1, 3A2, 3B, and 3C) (De Ferrari
et al., 1995).
Time-lapse videos of single beating iPSC-CMs under light
microscopy confirmed that electrophysiological deficiencies re-
sulted in contractile arrhythmia. Compared to control iPSC-CMs
(1.4% ± 1.9%; n = 68, 5 control subject lines), which had regular
beat intervals, HCM iPSC-CMs contained numerous cells
(12.4% ± 5.0%; n = 64, 5 patient lines) that beat at irregular
frequencies. Analysis of single-cell video recordings by pixel
quantification software confirmed the arrhythmic nature of
HCM iPSC-CM contraction, as well as hypercontractility of
diseased cells as compared to controls (Figures S4A–S4E) (Hos-
sain et al., 2010). Taken together, these findings demonstrate
sarcomeric mutations are capable of inducing electrophysiolog-
ical and contractile arrhythmia at the single-cell level.
Overexpression of the Arg663His Mutation in Normal
hESC-CMs Recapitulates Calcium Handling
Abnormalities of HCM iPSC-CMs
Calcium (Ca2+) plays a fundamental role in regulation of excita-
tion-contraction coupling and electrophysiological signaling in
the heart (Bers, 2008). To investigate the possible mechanisms
underlying arrhythmia in myocytes carrying the Arg663His muta-
tion, we next analyzed Ca2+ handling properties of iPSC-CMs
from control and HCM patients using the fluorescent Ca2+ dye
Fluo-4 acetoxymethyl ester (AM). Compared to iPSC-CMs
derived from healthy individuals, HCM iPSC-CMs demonstrated
significant Ca2+ transient irregularities such as multiple events
possibly related to triggered arrhythmia-like voltage waveforms,
which were virtually absent in control cells (Figures 3D and 3E
and Figures S4F–S4K). Interestingly, irregular Ca2+ transients
were observed to occur in HCM iPSC-CMs prior to the onset
of cellular hypertrophy, suggesting that abnormal Ca2+ handling
may be a causal factor for the induction of the hypertrophic
phenotype. Because variations inherent to spontaneous con-
tractions can potentially confound Ca2+ transients, we subjected
HCM and control iPSC-CMs to 1 Hz pacing during line scanning.
Consistent with data from spontaneous contraction, abnormal
Ca2+ transients were found to be common in HCM iPSC-CMs
(12.5% ± 4.9%; n = 19, 5 patient lines) and absent in control
iPSC-CMs (n = 20, 5 control subject lines) (Figures S4L–S4N
and Movie S2). To further ensure that observed deficiencies
in electrophysiology and Ca2+ regulation were due to the
Arg663His mutation, we next overexpressed the mutant form
of myosin in human embryonic stem cell-derived cardiomyo-
cytes (hESC-CMs; WA09 line). hESC-CMs overexpressing the
Arg663His mutantMYH7 transcript were found to exhibit similar
arrhythmias and abnormal Ca2+ transients (Figures 3F–3I).
Previous reports have linked intracellular Ca2+ ([Ca2+]i) eleva-
tion as a trigger for arrhythmia and cellular hypertrophy (Bers,ll Stem Cell 12, 101–113, January 3, 2013 ª2013 Elsevier Inc. 105
Figure 3. Assessment of Arrhythmia and Irregular Ca2+ Regulation in HCM iPSC-CMs
(A) Electrophysiological measurements of spontaneous action potentials in control and HCM iPSC-CMsmeasured by patch clamp in current-clampmode. Boxes
indicate underlined portions of HCM iPSC-CM waveforms at expanded timescales demonstrating DAD-like arrhythmias. See also Figures S3B–S3H.
(B) Quantification of DAD occurrence in control (n = 144, 5 control subject lines) and HCM (n = 131, 5 patient lines) iPSC-CMs. DAD rate is defined as total DADs/
total beats.
(C) Quantification of percentage of control (n = 144, 5 control subject lines) and HCM (n = 131, 5 patient lines) iPSC-CMs exhibiting putative DADs.
(D) Representative line-scan images and spontaneous Ca2+ transients in control and HCM iPSC-CMs. Red arrows indicate tachyarrhythmia-like waveforms
observed in HCM cells but not control. See also Figures S4A–S4E and Movie S2.
(E) Quantification of percentages for control and HCM iPSC-CMs exhibiting irregular Ca2+ transients at days 20, 30, and 40 after induction of cardiac differ-
entiation (n = 50, 5 control subject and 5 patient lines per time point).
(F) Representative line-scan images and spontaneous Ca2+ transients for H9 hESC-CMs and hESC-CMs stably transduced with lentivirus driving expression of
wild-type MYH7 or mutant MYH7 carrying the Arg663His mutation. Red arrowheads indicate irregular Ca2+ waveforms.
(legend continued on next page)
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Figure 4. Assessment of Intracellular Ca2+ Content in HCM iPSC-CMs
(A) Quantification of baseline Fluo-4 Ca2+ dye intensities for control (n = 122, 4 control subject lines) and HCM (n = 105, 4 patient lines) iPSC-CMs. See also Figures
S4F–S4N.
(B) Representative Ca2+ transients of control and HCM iPSC-CMs using the Indo-1 ratiometric Ca2+ dye.
(C) Quantification of resting Ca2+ levels by measurement of Indo-1 ratio in control (n = 21, 5 control subject lines) and HCM (n = 30, 5 patient lines) iPSC-CMs.
(D) Representative Ca2+ transient traces from control and HCM iPSC-CMs followed by caffeine exposure.
(E) Mean peak amplitudes of DF/F0 ratios after caffeine administration representing release of SR Ca2+ load for control (n = 36, 5 control subject lines) and HCM
(n = 44, 5 patient lines) iPSC-CMs.
(F) Quantification of irregular Ca2+ transients for control iPSC-CMs cultured in normal Ca2+ media (1.8 mM; n = 280, 5 control subject lines) and high Ca2+ media
(3.6 mM; n = 67, 5 control subject lines) for 2 hr.
(G) Quantification of DADs for control iPSC-CMs cultured in normal Ca2+ media (1.8 mM; n = 144, 5 control subject lines) and high Ca2+ media (3.6 mM; n = 32, 5
control subject lines) for 2 hr. *p < 0.05 HCM versus control, **p < 0.01 High Ca2+ versus normal Ca2+. Error bars represent SEM.
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[Ca2+]i in control and diseased iPSC-CMs. Preliminary quantifi-
cation of [Ca2+]i by Fluo-4 baseline intensity suggested that
[Ca2+]i was approximately 30% higher in HCM iPSC-CMs (n =
105, 4 patient lines) than control counterparts (n = 122, 4 control
subject lines) at day 30 postinduction (Figure 4A). To confirm
diastolic [Ca2+]i differences, we also used the ratiometric Ca
2+
dye Indo-1 in control and HCM iPSC-CMs. Indo-1 imaging
demonstrated that diastolic [Ca2+]i was higher (26.7% increase
in Indo-1 ratio) in iPSC-CMs carrying the Arg663His mutation
(n = 30, 5 patient lines) as compared to control cells (n = 21, 5
control subject lines) and that arrhythmic activity was apparent
in only the Arg663His myocytes. These findings emphasize
a role for irregular Ca2+ cycling in the pathogenesis of HCM
(Figures 4B and 4C). Measurement of sarcoplasmic reticulum
(SR) Ca2+ stores further supported findings of elevated [Ca2+]i
in diseased iPSC-CMs, as cytoplasmic retention of Ca2+ has
been shown to decrease SR Ca2+ load by impeding SR Ca2+(G) Quantification of cells exhibiting irregular Ca2+ transients in WA09 hESC-CMs
MYH7 carrying the Arg663His mutation (n = 40, 5 lines per group).
(H) Spontaneous action potentials recorded in current-clampmode for hESC-CMs
MYH7 carrying the Arg663His mutation. Red arrowheads indicate DAD-like wave
(I) Quantification of cells exhibiting DAD-like waveforms in hESC-CMs, hESC-CM
mutant MYH7 carrying the Arg663His mutation (n = 20, 5 lines per group). Error
Ceuptake (Semsarian et al., 2002). HCM and control iPSC-CMs
were loaded with Fluo-4 and exposed to caffeine, which induces
release of SR Ca2+ stores into the cytoplasm. Myocytes carrying
the Arg663His mutation were characterized by significantly
smaller SR Ca2+ release (mean peak DF/F0 ratio = 3.12 ± 0.19,
n = 44, 5 patient lines) as compared to control iPSC-CMs
(mean peak DF/F0 ratio = 4.08 + 0.22, n = 36, 5 control subject
lines) (Figures 4D and 4E). Finally, to ascertain that irregular
calcium transients and arrhythmia were caused by elevated
[Ca2+]i, we subjected control iPSC-CMs to culture in high Ca
2+
(3.6 mM) culture media. As compared to culture under normal
Ca2+ (1.8 mM) conditions, healthy iPSC-CMs cultured in high
Ca2+ media were found to develop both irregular Ca2+ transients
and arrhythmias similar to those observed in HCM iPSC-CMs
within 2 hr (Figures 4F and 4G). These findings demonstrate
a central role for Ca2+ cycling dysfunction and elevated [Ca2+]i
in the pathogenesis of HCM as caused by the Arg663His muta-
tion in MYH7., hESC-CMs overexpressing wild-typeMYH7, and hESC-CMs overexpressing
, hESC-CMs overexpressing wild-typeMYH7, and hESC-CMs overexpressing
forms.
s stably transduced with lentivirus driving expression of wild-type MYH7, or
bars represent SEM.
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Figure 5. Exacerbation of the HCM Phenotype by Positive Inotropic Stress
(A) Inotropic stimulation of control (n = 50, 5 control subject lines) and HCM (n = 50, 5 patient lines) iPSC-CMs by the b-agonist isoproterenol accelerated
presentation of cellular hypertrophy in HCM iPSC-CMs as compared to control counterparts. Coadministration of the b-blocker propranolol prevented
catecholamine-induced hypertrophy in HCM iPSC-CMs.
(B) Representative traces of MEA recordings for HCM and control multicellular iPSC-CM preparations. Treatment with 200 nM ISO increased both the beating
rate and the prevalence of putative DADs. Red arrowheads indicate putative DAD waveforms. See also Table S2 for baseline MEA measurements.
(C) Quantification of DAD waveforms in multicellular preparations of HCM iPSC-CMs before and after treatment with isoproterenol.
(D) Quantification of putative DAD rate in multicellular preparations of HCM iPSC-CMs before and after treatment with isoproterenol.
(legend continued on next page)
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in Diseased iPSC-CMs
Because iPSC-CMs carrying the Arg663His mutation recapitu-
lated numerous aspects of the HCM phenotype in vitro, we
hypothesized that our platform could also be used as a screening
tool to assess the effect of pharmaceutical drugs upon HCM at
the single-cell level. To test the capacity of HCM iPSC-CMs to
accurately model pharmaceutical drug response, we first sub-
jected single control and diseased iPSC-CMs to positive
inotropic stimulation, a known trigger for myocyte hypertrophy
and ventricular tachycardia (Fatkin and Graham, 2002; Knoll-
mann et al., 2003). Patient-specific cardiomyocytes were incu-
batedwith b-adrenergic agonist (200 nM isoproterenol) on a daily
basis for 5 days beginning 30 days after induction of differentia-
tion. Previously, HCM iPSC-CMs typically did not exhibit cellular
hypertrophy until day 40 postinduction (Figure 2B) but were
found to increase in cell size by 1.7-fold between day 30 and
35 as compared to control counterparts when treated with
isoproterenol (Figure 5A). b-adrenergic stimulation was also
found to severely exacerbate presentation of irregular Ca2+
transients and arrhythmia in both single and multicellular prepa-
rations of HCM iPSC-CMs (Figures 5B–5H). Importantly, coad-
ministration of b-adrenergic blocker (400 nM propranolol) with
isoproterenol significantly ameliorated catecholamine-induced
exacerbation of hypertrophy, Ca2+ handling deficiencies, and
arrhythmia.
Treatment of Ca2+ Dysregulation Prevents Development
of the HCM Phenotype
We next assessed whether pharmaceutical inhibition of Ca2+
entry could help prevent HCM phenotype development by treat-
ing control and mutant iPSC-CMs with the L-type Ca2+ channel
blocker verapamil. Compared to control cells, the spontaneous
beating rate in HCM iPSC-CMs was relatively resistant to verap-
amil as detected by MEA dose-response experiments (HCM
IC50 = 930.61 ± 80.0 nM, 5 patient lines; control IC50 = 103.0 ±
6.0 nM, 5 control subject lines), consistent with the elevated
[Ca2+]i in iPSC-CMs carrying the Arg663His mutation (Figures
S5A–S5D). Remarkably, continuous addition of verapamil at
therapeutic dosages (50–100 nM) to single diseased iPSC-
CMs for 10–20 sequential days significantly ameliorated all
aspects of the HCM phenotype including myocyte hypertrophy,
Ca2+-handling abnormalities, and arrhythmia (Figures 6A–6C).
To ensure the pharmaceutical effects observed were specific
to Ca2+ channel inhibition, we repeated treatment of both single
and multicellular preparations of HCM iPSC-CMs with the Ca2+
channel blockers nifedipine and diltiazem. As with verapamil,
beating rate of HCM iPSC-CMs demonstrated a higher resis-
tance to nifedipine (HCM IC50 = 2.3 ± 0.31 mM, n = 8, 5 patient
lines) than control cells (control IC50 = 0.03 ± 0.005 mM, n = 13,(E) Representative Ca2+ line scans and waveforms in control and HCM iPSC-CMs
abnormal Ca2+ waveforms.
(F) Quantification of control (n = 50, 5 control subject lines) andHCM (n = 50, 5 patie
by isoproterenol and coadministration of propranolol.
(G) Electrophysiological measurement of spontaneous action potentials and arrhy
stimulation by isoproterenol. Red arrows indicate DAD-like waveforms.
(H) Quantification of DAD rate in control and HCM iPSC-CMs after isoproterenol ad
HCM versus control, ##p < 0.01 iso + pro versus iso. Error bars represent SEM.
Ce5 control subject lines). Diltiazem, which is more specific to
Ca2+ channel inhibition than verapamil, also abolished Ca2+-
handling abnormalities and arrhythmia in HCM iPSC-CMs
(Figure 6D and Figures S5E and S5F).
Arrhythmic iPSC-CMs Can Be Screened for Potential
Pharmaceutical Treatments at the Single-Cell Level
As current pharmaceutical therapy for HCM includes the use of
b-blockers and antiarrhythmics in addition to Ca2+ channel
blockers, we further screened a panel of 12 other drugs used
clinically to treat HCM for their potential to ameliorate the HCM
phenotype at the single-cell level (Table S3). While verapamil
was the only agent found to be capable of preventing cellular
hypertrophy, antiarrhythmic drugs that inhibit Na+ influx such
as lidocaine, mexiletine, and ranolazine also demonstrated
potential to restore normal beat frequency in HCM iPSC-CMs,
possibly through limiting Ca2+ entry into the cell by the Na+/
Ca2+ exchanger (Figures S6A–S6F, Movie S3). Other antiar-
rhythmic agents targeting K+ channels and b-blockers adminis-
tered in the absence of inotropic stimulation did not have any
therapeutic effects in single cells. Altogether, these results
strongly implicate imbalances in Ca2+ regulation as a central
mechanism underlying development of HCM at the cellular level
and demonstrate the potential of patient-specific iPSC-CMs as
a powerful tool for the identification of novel pharmaceutical
agents to treat HCM.
DISCUSSION
The genetic causes of HCM were initially identified several
decades ago (Geisterfer-Lowrance et al., 1990). However, the
mechanisms by which sarcomeric gene mutations engender
the HCM phenotype remain unclear. Modern understanding of
HCM is largely based upon transgenic animals engineered to
carry human HCM mutations in the murine a-myosin backbone.
While these animal models have yielded significant insights into
the development of HCM, they also suffer from several limita-
tions that prevent adequate modeling of human cardiac disease.
For example, the predominant myosin isoform found in the
human cardiac sarcomere is b-myosin, which is largely absent
in a-myosin-enriched murine hearts (Fatkin et al., 1999; Lompre
et al., 1981). This is especially important in the context of HCM,
as b-myosin is the most common causal gene to be mutated for
the disease (Seidman and Seidman, 2001). A recent study high-
lighted the differences in biophysical properties of a- and
b-myosin by cloning the same human HCM mutation (R403Q)
into both the a-myosin backbone and the b-myosin backbone
(Lowey et al., 2008). Remarkably, the same R403Q mutation
resulted in completely different functional consequences for
myosin contraction depending on whether it was expressed inafter positive inotropic stimulation by isoproterenol. Red arrowheads indicate
nt lines) iPSC-CMs exhibiting irregular Ca2+ transients in response to treatment
thmia in control and HCM iPSC-CMs at baseline, followed by positive inotropic
ministration (total DADs/total beats). *p < 0.05 HCM versus control, **p < 0.001
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Figure 6. Treatment of HCM iPSC-CMs by Ca2+ Channel Inhibition Significantly Mitigates Development of the HCM Phenotype
(A) Representative immunostaining images of HCM iPSC-CMs treated with 0 nM, 50 nM, and 100 nM of the L-type Ca2+ channel blocker verapamil for 5
continuous days beginning 25 days after induction of cardiac differentiation. Quantification of relative cell sizes for HCM iPSC-CMs treated with verapamil (n = 50,
5 patient lines per treatment group).
(B) Representative Ca2+ line scan images and waveforms of HCM iPSC-CMs treated with 0 nM, 50 nM, and 100 nM of verapamil for 5 continuous days. Quan-
tification of percentages of HCM iPSC-CMs found to exhibit irregular Ca2+ transients after treatment with verapamil (n = 40, 5 patient lines per treatment group).
(C) Representative electrophysiological recordings of spontaneous action potentials in HCM iPSC-CMs treated with 0 nM, 50 nM, and 100 nM of verapamil for 5
continuous days. Quantification of DAD frequencies in HCM iPSC-CMs after treatment with verapamil (n = 25, 5 patient lines per treatment group). See also
Figures S5A–S5F.
(legend continued on next page)
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in conflicting results for animal studies modeling HCM (Arad
et al., 2002; Marian et al., 1997; Tyska et al., 2000).
Generation of patient-specific iPSC-CMs circumvents many
of the limitations associated with transgenic animal models
and has previously been used to model several hereditary
cardiovascular disorders in vitro including dilated cardiomyop-
athy, LEOPARD, and long QT syndrome (Carvajal-Vergara
et al., 2010; Itzhaki et al., 2011; Moretti et al., 2010; Narsinh
et al., 2011a; Sun et al., 2012; Yazawa et al., 2011). To elucidate
the mechanisms underlying HCM development, we utilized iPSC
technology to generate functional cardiomyocytes from dermal
fibroblasts of a ten-member family cohort, half of whom possess
the HCMArg663His mutation in theMYH7 gene. Patient-specific
iPSC-CMs recapitulated a number of characteristics of HCM
including cellular hypertrophy, calcineurin-NFAT activation, up-
regulation of hypertrophic transcription factors, and contractile
arrhythmia. Irregular Ca2+ transients and elevation of diastolic
[Ca2+]i were observed to precede the presentation of other
phenotypic abnormalities, strongly implicating dysregulation of
Ca2+ cycling as a central mechanism for pathogenesis of the
disease.
Imbalances in Ca2+ homeostasis have been described as
a key characteristic of HCM in numerous reports (Fatkin et al.,
2000; Semsarian et al., 2002). However, little evidence exists
to delineate whether these abnormalities are a symptom of
HCM or a causal factor. In this study, we present several lines
of evidence for a crucial role of Ca2+ in development of HCM
as caused by the Arg663His mutation. Specifically, our findings
suggest that an elevation in [Ca2+]i mediated by the Arg663His
mutation can induce both cellular hypertrophy and contractile
arrhythmia (Figure 6E) (Fatkin and Graham, 2002). The sustained
elevation of [Ca2+]i is a known trigger for activation of calcineurin,
a Ca2+-dependent phosphatase that is a critical effector of
hypertrophy in myocytes under conditions of stress. Activated
calcineurin dephosphorylates NFAT3 transcription factors,
allowing their translocation to the nucleus for direct interaction
with classical mediators of hypertrophy such as GATA4 and
MEF2 (Molkentin et al., 1998; Sussman et al., 1998). Time-based
gene expression profiling of single iPSC-CMs after induction of
cardiac differentiation confirmed this model as expression of
downstream effectors of hypertrophy was observed to be
dependent on [Ca2+]i elevation and nuclear translocation of
NFAT. Inhibition of calcineurin activity by CsA and FK506 as
well as reduction of Ca2+ influx by verapamil mitigated cellular
hypertrophy, confirming the role of Ca2+ dysfunction and calci-
neurin-NFAT signaling in HCM pathogenesis.
Alterations in Ca2+ cycling are a common trigger for cardiac
arrhythmias, which are a serious clinical complication of HCM
due to their potential to induce stroke or sudden cardiac death
(Bers, 2008). The mechanisms underlying arrhythmia in patients
with HCM are not well understood, although reports have impli-
cated interstitial fibrosis, abnormal cardiac anatomy, myocyte(D) Plots of average beat frequencies for control and HCM iPSC-CM EBs agains
HCM IC50 values for spontaneous beat frequency against nifedipine (HCM, n = 8
(E) Schematic for development of the HCM phenotype as caused by HCMmutatio
the disease. See also Figures S6A–S6E, Table S3, and Movie S3. *p < 0.01 untrea
control. Error bars represent SEM.
Cedisarray, increased cell size, and dysfunction in Ca2+ homeo-
stasis as possible mediators (Adabag et al., 2008; Wolf et al.,
2005). Our findings demonstrate that the Arg663His mutation
in the MYH7 gene can directly result in electrophysiological
and contractile arrhythmia at the single-cell level even in the
absence of cellular hypertrophy. The most likely mechanism for
development of arrhythmia in individual HCM iPSC-CMs is
buildup of [Ca2+]i, which induces DADs, whereby sarcoplasmic
reticulum Ca2+ release triggers transient inward current after
action potential repolarization (Berlin et al., 1989; Bers, 2008;
De Ferrari et al., 1995). Continued presentation of DADs can in
turn lead to ventricular tachycardia and sudden cardiac death,
as in patients suffering from recurrent arrhythmia (Iyer et al.,
2007). Whole-cell current-clamp experiments of HCM iPSC-
CMs supported this hypothesis through demonstration of
frequent spontaneous DAD-like waveforms in diseased myo-
cytes.We believe these results are the first report to demonstrate
that HCMmutations such as Arg663His can act as direct triggers
for arrhythmia at the single-cell level.
The hypothesis that dysfunction in Ca2+ homeostasis engen-
ders the HCM phenotype was first proposed over a decade
ago and is linked to the theory that HCM mutations increase
myofilament Ca2+ affinity and cause ‘‘ion trapping’’ of Ca2+ in
the cytoplasm (Fatkin et al., 2000; Semsarian et al., 2002).
Although it is not entirely clear how the enhanced Ca2+ affinity
would elevate free diastolic [Ca2+]i as we have measured here,
the mechanistic role of elevated myocyte Ca2+ loading seems
to be central to both hypertrophy and arrhythmogenesis. Phar-
maceutical drug screening of mutant iPSC-CMs further sup-
ported elevated [Ca2+]i as a central mechanism for arrhythmia
development. Of the 13 agents we used, only pharmaceutical
blockade of Ca2+ and Na+ entry mitigated contractile arrhythmia
in HCM iPSC-CMs. Reduction of Na+ influx limits [Ca2+]i by al-
lowing Na+/Ca2+ exchange to remove Ca2+ more readily. Our
results demonstrate the utility of iPSC-based technology to
model development of HCM and associated triggered arrhyth-
mias, as well as to identify potential therapeutic agents for the
disease.
It is important to note that there are several limitations to our
study. First, as described by several other reports, both hESC-
CMs and iPSC-CMs are developmentally immature and are
characterized by gene expression profiles similar to fetal cardio-
myocytes, as well as lower levels of b-myosin than adult cardio-
myocytes (Burridge et al., 2012; Cao et al., 2008; Carvajal-
Vergara et al., 2010; Itzhaki et al., 2011). Second, iPSC-CMs
are not able to model disease phenotypes that present at the
tissue level such as interstitial fibrosis, scarring, and myocyte
disarray. Finally, over 1,000 unique mutations have been identi-
fied to cause HCM, and our findings may only be specific to the
Arg663His mutation. In spite of these limitations, we believe that
our results are the first to provide direct evidence of elevation in
[Ca2+]i as an initiating factor in the development of HCM at the
single-cell level. We anticipate that future studies utilizingt nifedipine concentration fit to the Hill equation. Quantification of control and
, 5 patient lines, control n = 13, 5 control subject lines).
ns in MYH7. Red boxes indicate potential methods to mitigate development of
ted versus 50 nM verapamil versus 100 nM verapamil. **p < 0.001 HCM versus
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tion of how mutations in the thick filament cause Ca2+ handling
defects as well as identification of alternative mechanisms
underlying development of HCM.
EXPERIMENTAL PROCEDURES
Generation of Patient-Specific iPSCs
Protocols for this study were approved by the Stanford University Human
Subjects Research Institutional Review Board and written consent was
obtained from all study participants. Dermal fibroblasts were isolated from
all family members and passaged three times before lentiviral infection with
OCT4, SOX2, KLF4, and c-MYC. Colonies with iPSC morphology were lifted
and maintained on Matrigel-coated plates (BD Biosciences) for maintenance
with mTESR-1 growth medium (StemCell Technologies) as previously
described (Sun et al., 2012).
Cardiac Differentiation of Patient-Specific iPSCs
Established iPSC lines from all subjects were differentiated into cardiomyo-
cyte lineages (iPSC-CMs) using standard 3D EB differentiation protocols
as previously described (Yang et al., 2008). For single cardiomyocyte
analyses, beating EBs were plated on gelatin-coated dishes for 3 days, trypsi-
nized, strained through a 40-mm-size pore-size filter, and replated as single
cells on low density on gelatin-coated chamber slides (Nalgene Nunc
International).
Ca2+ Imaging Using Fluo-4 AM
iPSC-CMs were dissociated from beating EBs and seeded in gelatin-coated
8-well LAB-TEK II chambers (Nalgene Nunc International). Cells were loaded
with 5 mM Fluo-4 AM and imaged in Tyrodes solution using a confocal micro-
scope (Carl Zeiss, LSM 510 Meta) at 403. Spontaneous Ca2+ transients were
recorded at 37C using standard line-scan methods (Yazawa et al., 2011). A
total of 10,000 line scans were acquired for durations of 19.2 s. For paced
Ca2+ dye imaging, cells were stimulated at 1 and 2 Hz. Videos were taken at
20 fps for 10 s recording durations.
Patch Clamping
Whole-cell patch-clamp recordings were conducted on single beating cardio-
myocytes at 36C–37C using an EPC-10 patch-clamp amplifier (HEKA) and
a RC-26C recording chamber (Warner) mounted on to the stage of an inverted
microscope (Nikon). Data were acquired using PatchMaster software (HEKA)
and digitized at 1.0 kHz. Current-clamp recordings were conducted in Tyrodes
solution.
Drug Treatment
Single contracting iPSC-CMs were treated with pharmaceutical agents for
10min for immediate analysis followed by washout. The respective concentra-
tions of each drug tested are listed in Table S3. For inotropic stimulation exper-
iments, 200 nM isoproterenol and 400 nM propranolol were added to the cell
medium for 5 continuous days. Verapamil treatment was conducted by adding
50 nM and 100 nM to the culture medium of iPSC-CMs for 10–20 continuous
days on a daily basis.
Statistical Analysis
Statistical differences between two groups were determined using the two-
tailed Student t tests. Statistical differences among more than two groups
were analyzed by one-way ANOVA followed by Tukey’s multiple comparison
test. Denotation of a patient or control subject line is defined as one patient-
specific line from one distinct individual.
A complete description of the methods is detailed in the Supplemental
Experimental Procedures section.
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